Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Gilead Sciences’ (NASDAQ: GILD) Q2 earnings are scheduled to be released on August 7, after market close. The pharma company ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence ...

President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S.

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over ...